A Phase 3 interventional study of ONO-4538 and Carboplatin in Non-Small Cell Lung Cancer, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 135 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.
Sponsored by Ono Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 24 that started in 2017, is one of 24 in phase 3, and was the 44th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 24 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 550 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 62 that completed or were terminated, 44 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Ono Pharmaceutical Co. Ltd has 9 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-naïve subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation in a multicenter, randomized, double-blind study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Drug: ONO-4538 · Drug: Carboplatin · Drug: Paclitaxel · Drug: Bevacizumab
Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Drug: Carboplatin · Drug: Paclitaxel · Drug: Bevacizumab · Drug: Placebo
360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC)
PFS (as assessed by the IRRC) will be calculated using the following formula : PFS (days) = "date when overall response is assessed as progressive disease (PD) or date of death (for any reason), whichever comes first" - "date of randomization" + 1. Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.
Time frame: Approximately 32 months
Overall Survival (OS)
Time frame: Approximately 32 months
Objective Response Rate (ORR [as Assessed by the IRRC])
ORR represents the proportion of subjects whose best overall response was assessed as complete response (CR) or partial response (PR). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.
Time frame: Approximately 32 months
Disease Control Rate (DCR [as Assessed by the IRRC])
DCR represents the proportion of subjects whose best overall response was assessed as CR, PR, or stable disease (SD). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.
Time frame: Approximately 32 months
Duration of Response (DOR [as Assessed by the IRRC])
The lower and upper limits of 95% CI for the median are censored value in the both groups.
Time frame: Approximately 32 months
Best Overall Response (BOR [as Assessed by the IRRC])
Time frame: Approximately 32 months
| Milestone | ONO-4538 Group | Placebo Group |
|---|---|---|
| Started | 275 | 275 |
| Completed | 74 | 44 |
| Not completed | 201 | 231 |
| Withdrew: Continued the follow-up period | 109 | 129 |
| Withdrew: Died | 82 | 93 |
| Withdrew: Consent withdrawal | 7 | 6 |
| Withdrew: Missing contact | 3 | 3 |
PFS (as assessed by the IRRC) will be calculated using the following formula : PFS (days) = "date when overall response is assessed as progressive disease (PD) or date of death (for any reason), whichever comes first" - "date of randomization" + 1. Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.
| months | ONO-4538 Group | Placebo Group |
|---|---|---|
| Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC) | 12.1 (9.8 to 14.0) | 8.1 (7.0 to 8.5) |
| months | ONO-4538 Group | Placebo Group |
|---|---|---|
| Overall Survival (OS) | 25.4 (21.8 to NA) | 24.7 (20.2 to NA) |
ORR represents the proportion of subjects whose best overall response was assessed as complete response (CR) or partial response (PR). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.
| percentage of participants | ONO-4538 Group | Placebo Group |
|---|---|---|
| Objective Response Rate (ORR [as Assessed by the IRRC]) | 61.5 (55.4 to 67.2) | 50.5 (44.5 to 56.6) |
DCR represents the proportion of subjects whose best overall response was assessed as CR, PR, or stable disease (SD). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.
| percentage of participants | ONO-4538 Group | Placebo Group |
|---|---|---|
| Disease Control Rate (DCR [as Assessed by the IRRC]) | 87.3 (82.7 to 91.0) | 89.8 (85.6 to 93.1) |
The lower and upper limits of 95% CI for the median are censored value in the both groups.
| months | ONO-4538 Group | Placebo Group |
|---|---|---|
| Duration of Response (DOR [as Assessed by the IRRC]) | 11.0 (1.1 to 25.8) | 7.0 (1.2 to 26.0) |
| Participants | ONO-4538 Group | Placebo Group |
|---|---|---|
| Complete response | 14 | 8 |
| Partial response | 155 | 131 |
| Stable disease | 71 | 108 |
| Progressive disease | 5 | 11 |
| Not evaluable | 30 | 17 |
Collected over For each randomised subject, adverse events(AEs) were collected from the start date of administration of the investigational product to 30 days after the last dose of any of the study treatment (The maximum was about 30 months). Drug-related AEs or AEs leading to discontinuation reported at the start of follow-up should be investigated at appropriate intervals until no further follow-up is required because the events have resolved or are resolving, or the symptoms become stable.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ONO-4538 Group | 82/275 (29.8%) | 154/273 (56.4%) | 271/273 (99.3%) |
| Placebo Group | 93/275 (33.8%) | 118/275 (42.9%) | 274/275 (99.6%) |
| Event | ONO-4538 Group | Placebo Group |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 27/273 | 12/275 |
| PneumoniaInfections and infestations | 21/273 | 15/275 |
| PyrexiaGeneral disorders | 16/273 | 4/275 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 9/273 | 0/275 |
| ColitisGastrointestinal disorders | 8/273 | 1/275 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 8/273 | 5/275 |
| Decreased appetiteMetabolism and nutrition disorders | 5/273 | 8/275 |
| Adrenal insufficiencyEndocrine disorders | 7/273 | 1/275 |
| Neutrophil count decreasedInvestigations | 6/273 | 0/275 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 6/273 | 3/275 |
| Event | ONO-4538 Group | Placebo Group |
|---|---|---|
| ConstipationGastrointestinal disorders | 150/273 | 134/275 |
| AlopeciaSkin and subcutaneous tissue disorders | 143/273 | 150/275 |
| Neutrophil count decreasedInvestigations | 117/273 | 141/275 |
| Peripheral sensory neuropathyNervous system disorders | 121/273 | 116/275 |
| Decreased appetiteMetabolism and nutrition disorders | 98/273 | 108/275 |
| AnaemiaBlood and lymphatic system disorders | 88/273 | 102/275 |
| NauseaGastrointestinal disorders | 86/273 | 100/275 |
| White blood cell count decreasedInvestigations | 94/273 | 99/275 |
| RashSkin and subcutaneous tissue disorders | 96/273 | 48/275 |
| MyalgiaMusculoskeletal and connective tissue disorders | 76/273 | 92/275 |
| Age, Continuous(years) | ONO-4538 Group | Placebo Group | Total |
|---|---|---|---|
| Median | 66 (27 to 85) | 66 (33 to 83) | 66 (27 to 85) |
| Age, Customized(Participants) | ONO-4538 Group | Placebo Group | Total |
|---|---|---|---|
| <65 years | 131 | 111 | 242 |
| 65-74 years | 117 | 131 | 248 |
| >=75 years | 27 | 33 | 60 |
| Sex: Female, Male(Participants) | ONO-4538 Group | Placebo Group | Total |
|---|---|---|---|
| Female | 70 | 69 | 139 |
| Male | 205 | 206 | 411 |
| Race (NIH/OMB)(Participants) | ONO-4538 Group | Placebo Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 275 | 275 | 550 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Country(Participants) | ONO-4538 Group | Placebo Group | Total |
|---|---|---|---|
| Japan | 188 | 183 | 371 |
| Korea | 62 | 63 | 125 |
| Taiwan | 25 | 29 | 54 |
| ECOG Performance Score(Participants) | ONO-4538 Group | Placebo Group | Total |
|---|---|---|---|
| 0 | 129 | 128 | 257 |
| 1 | 146 | 147 | 293 |
| Smoking status(Participants) | ONO-4538 Group | Placebo Group | Total |
|---|---|---|---|
| Never | 61 | 54 | 115 |
| Current | 18 | 21 | 39 |
| Former | 196 | 200 | 396 |
| Staging (the UICC-TNM classification, 7th edition)(Participants) | ONO-4538 Group | Placebo Group | Total |
|---|---|---|---|
| Stage IIIB | 15 | 14 | 29 |
| Stage IV | 239 | 238 | 477 |
| Recurrent | 21 | 23 | 44 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 135 sites across 3 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Feb 2020, 31 months.
Results were first posted in Apr 2022, 2 years 2 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 31 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Carcinoma, Non-Small-Cell Lung →